Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 10 clinical trials
Well-Being After Breast Cancer Surgery (WB ABCs)

breast surgery for lobular carcinoma in situ (LCIS), ductal carcinoma in situ (DCIS), or invasive breast cancer, and to examine the roles of psychological and physiological variables as modifiable

  • 0 views
  • 07 Jul, 2022
  • 2 locations
Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ

Although the results obtained from ECOG E5194 cohort 1 (criteria: mammographically detected low- or intermediate-grade DCIS, measuring less than 2.5 cm with margins 3 mm) and RTOG 9804 trial (the same enrolled clinicopathological features to cohort 1 of ECOG E5194 trial) demonstrated that the 7-year ipsilateral breast tumor recurrence (IBTR) …

estrogen
breast cancer
breast tumor
breast-conserving surgery
radiotherapy to breast
  • 18 views
  • 14 Feb, 2022
  • 1 location
A Phase IIB Randomized Trial of Oral Tamoxifen vs. Topical 4-hydroxytamoxifen Gel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ

The investigators plan to prospectively study breast tissue changes after a short course of Tamoxifen (Tam).

  • 2 views
  • 28 Oct, 2022
  • 2 locations
Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)

This trial studies the implementation of web-based decision support tools for patients with atypical hyperplasia or lobular carcinoma in situ and healthcare providers. Decision support tools are

Accepts healthy volunteers
  • 0 views
  • 23 Mar, 2022
  • 19 locations
Ruxolitinib for Premalignant Breast Disease (TBCRC042)

This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive a placebo (sugar pill) for approximately 15 days. Once study participants have completed their ruxolitinib or placebo, participants will undergo surgery …

neutrophil count
antifungals
lobular carcinoma
ductal hyperplasia
atypical ductal hyperplasia
  • 49 views
  • 23 May, 2022
  • 7 locations
Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer (MAPBI)

This trial will investigate a novel 3-fraction radiation regimen for participants undergoing breast-conserving therapy (BCT) for early breast cancer that will: 1) significantly reduce the duration of treatment and can be completed in one-week (5 working days) and 2) MRI-guided radiotherapy (MRIdian) would limit the volume of normal tissue radiated …

invasive carcinoma
ductal carcinoma in situ
breast cancer
breast-conserving surgery
breast irradiation
  • 1 views
  • 26 May, 2022
  • 1 location
Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer

Single-arm, phase 2 study evaluating hypofractionated irradiation of breast and regional nodes in women with breast cancer. Patients will be grouped in 3 surgery-related treatment groups: 1) An intact breast following lumpectomy; 2) plans for loco regional external beam radiotherapy (EBRT) following mastectomy (with or without plans for reconstruction); and …

progesterone receptor
HER2
sentinel lymph node biopsy
lobular carcinoma
epidermal growth factor
  • 18 views
  • 26 Dec, 2021
  • 2 locations
Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

This phase II trial studies how well abemaciclib works in treating patients with triple negative breast cancer that can be removed by surgery (resectable) and does not respond to treatment with chemotherapy. Abemaciclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

progesterone receptor
HER2
therapeutic conventional surgery
dcis
residual tumor
  • 13 views
  • 15 Jul, 2022
  • 3 locations
LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients (LobularCard)

This is a cross-sectional and retrospective study of a cohort of patients with invasive lobular breast cancer (LBC) or in situ lobular neoplasia (LIN3). The main endpoint is the relative frequency of patients with a germline mutation using a recent panel including 113 genes from the "Illumina" protocol. In case …

  • 0 views
  • 14 Oct, 2022
  • 1 location
Characterization of High-Risk Breast Duct Epithelium by Cytology, Breast Duct Endoscopy, and cDNA Gene Expression Profile

/2 or other hereditary genes mutation carriers. Women with cytologic or histologic evidence of ductal hyperplasia, atypical ductal hyperplasia, or lobular carcinoma in situ. Women

ductal carcinoma in situ
lobular carcinoma
ductal carcinoma
mammogram
BRCA1/2
  • 8 views
  • 28 Oct, 2022
  • 1 location